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Abstract
Background: The electrolytic inferior vena cava model (EIM) is a murine venous thrombo-
sis (VT) model that produces a non- occlusive thrombus. The thrombus forms in the direc-
tion of blood flow, as observed in patients. The EIM is valuable for investigations of 
therapeutics due to the presence of continuous blood flow. However, the equipment used 
to induce thrombosis in the original model description was expensive and has since been 
discontinued. Further, the fibrinolytic system had not been previously studied in the EIM.
Objectives: We aimed to provide an equipment alternative. Additionally, we further 
characterized the model through mapping the current and time dependency of thrombus 
resolution dynamics, and investigated the fibrinolytic system from acute to chronic VT.
Results: A voltage to current converter powered by a direct current power supply was 
constructed and validated, providing an added benefit of significantly reducing costs. 
The current and time dependency of thrombus volume dynamics was assessed by MRI, 
demonstrating the flexibility of the EIM to investigate both pro- thrombotic and anti- 
thrombotic conditions. Additionally, the fibrinolytic system was characterized in EIM. 
Centripetal distribution of plasminogen was observed over time, with peak staining at 
day 6 post thrombus induction. Both active circulating plasminogen activator inhibitor-
 1 (PAI- 1) and vein wall gene expression of PAI- 1 peaked at day 2, coinciding with a rela-
tive decrease in tissue plasminogen activator and urokinase plasminogen activator.
Conclusions: The EIM is a valuable model of VT that can now be performed at low cost 
and may be beneficial in investigations of the fibrinolytic system.
K E Y W O R D S
animal models, eim, electrolysis, fibrinolysis, magnetic resonance imaging, veins, venous 
thromboembolism, venous thrombosis
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1  | INTRODUCTION
Animal models are critical to study the biology of venous thrombosis 
(VT). The electrolytic inferior vena cava model (EIM) was developed 
to simulate VT in the clinical scenario of a non- occlusive thrombus. 
By applying a small constant current to a copper wire inserted into 
the inferior vena cava (IVC), free radicals are released which activate 
endothelial cells and initiate the thrombotic process in the constant 
presence of blood flow. These conditions mimic the clinical scenario 
of a non- occlusive thrombus (Figure 1).1–3 This method produces a 
thrombus that is highly consistent in size. The EIM has been used in the 
United States and beyond to study VT in both anti- thrombotic and pro- 
thrombotic conditions, demonstrating the flexibility of the model.4,5
Since the initial development of the EIM in 2010, several chang-
ing circumstances have driven a need for an update on the model. 
First, the originally described stimulator equipment was expensive and 
has since been discontinued. Second, the dependence of thrombus 
size on current and time were assumed, but had not previously been 
demonstrated. Third, increasing interest in targeting the fibrinolytic 
system for treatment of VT and the results of the ATTRACT trial em-
phasize a need for basic science evidence on the fibrinolytic system 
of thrombi in the presence of blood flow.6,7 The EIM provides a favor-
able environment for such therapeutic targets due to the sustained 
blood flow access to the thrombus. However, the fibrinolytic system 
had not previously been investigated in the EIM. In this communica-
tion, we addressed all three of these important updates; we devel-
oped an equipment alternative to the previously described system, 
investigated the current and time dependency of thrombus size, and 
characterized the fibrinolytic system in the EIM.
2  | MATERIALS AND METHODS
2.1 | Mice and EIM surgical procedure
All experiments were performed at the University of Michigan with ap-
proval from the University of Michigan’s Institutional Animal Care and 
Use Committee (IACUC) and conducted in accordance with The Guide 
for the Care and Use of Laboratory Animals.8 Male C57BL/6 mice aged 
10- 12 weeks were anesthetized with 2% isoflurane, placed in dorsal 
recumbency, and a midline laparotomy was performed. The IVC was 
exposed, any lateral branches were ligated using 7- 0 Prolene suture 
(Ethicon, Inc., Somerville, NJ), and back branches remained patent. A 30- 
gauge silver coated copper wire (KY- 30- 1- GRN, Electrospec, Dover, NJ, 
USA) with exposed copper wire at the end was attached to a 25- gauge 
needle and inserted into the IVC and positioned against the anterior wall 
(anode). Another needle was implanted subcutaneously at the proximal 
end of the laparotomy incision, completing the circuit (cathode). A de-
tailed video demonstrating the surgical technique is available.3
A constant current of 250 μA was applied for 15 minutes for 
standard procedures.3 To investigate the current and time depen-
dency of the EIM, either the current or time was modified to 100 μA 
or 7.5 minutes, respectively. The current was supplied by either the 
previously described Grass S48 square wave stimulator and constant 
current unit (Grass Technologies, Astro- Med, Inc., West Warwick, RI), 
or by the voltage- to- current converter, described below (Figure 2). 
Essentials
• Three key updates are provided on the electrolytic inferior vena cava model (EIM).
• The originally described stimulator equipment has been discontinued; we developed an alternative.
• The fibrinolytic system and the current and time dependency of the EIM was characterized.
• EIM allows the investigation of the fibrinolytic system, critical for endovascular therapies.
F IGURE  1  (A) Schematic representation 
of the EIM. Any lateral branches draining 
into the IVC distal to the left renal vein are 
ligated, and a 250 μA current is applied to 
a copper wire placed within the IVC against 
the anterior wall. The right lymph node, 
consistently located near the bifurcation, 
serves as an anatomical reference for 
placement of the 25- gauge needle 
containing the copper wire. (B) Gross 
anatomy images of the thrombus and vein 
wall at day 2 harvest; line markings denote 
mm. EIM, electrolytic inferior vena cava 
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The direct current results in the release of free radicals within the IVC, 
which in turn activate endothelial cells and initiate a thrombogenic 
environment in the constant presence of blood flow. The needle was 
then removed and the abdomen closed in two layers; the muscle and 
peritoneum was closed with 5- 0 Vicryl (Ethicon, Inc., Somerville, NJ, 
USA), the skin closed with Vetbond (3M, St. Paul, MN, USA).
Mice not undergoing magnetic resonance imaging (MRI) were 
euthanized at specific time points post thrombosis in order to an-
alyze thrombus weight and perform histology, PCR, or ELISA. True 
controls (TC), surgically naïve mice, were utilized for baseline mo-
lecular assays.
2.2 | EIM equipment
EIM was performed either with the previously described discontinued 
stimulator and constant current unit, or with a voltage to current con-
verter (VIC), as pictured in Figure 2. The AD620 operation amplifier 
may be used in conjunction with a second operational amplifier, such 
as the AD705 (DigiKey, Thief River Falls, MN, USA). A 40 kΩ resistor 
(R1) was used with an input voltage of +5 and - 5 volts, but the desired 
resistor and/or voltage may be calculated based on the input current 
as follows:
where IL is the current applied to the load, typically 250 μA, R1 is the 
resistor used, VIN is the positive and negative input voltage, and G is the 
gain. A gain resistor (RG) is not needed for this application, so the gain (G) 
remains at 1. The circuit was powered by a DC power supply (Agilent 
E3630A, KeySight Technologies, Santa Rosa, CA, USA). Prior to surgery, 
a sample load resistor (e.g. 100 Ω) was connected to the circuit and a 
multimeter was connected in series to fine tune the supplied voltage to 
deliver 250 μA (or desired current) to the load.
2.3 | Validation and characterization
In vivo validation of the VIC was performed by comparing thrombus 
weights at days 2, 6, and 11- post thrombus induction against thrombi 
produced using the stimulator and constant current unit. Following 
validation, the vein wall was isolated for qRT- PCR analysis, and 500 μL 
of blood was collected for circulating plasminogen activator inhibitor 
(PAI)- 1 activity assay. EIM was performed in a separate group of mice 
for immunohistochemistry at the same time points.
Additionally, to investigate the current and time dependency of 
the EIM, thrombus was induced in three groups: standard, 250 μA for 
15 min; reduced current, 100 μA for 15 min; and reduced time, 250 μA 
for 7.5 min. Thrombus volume was followed over time using MRI, de-
scribed below.
2.4 | Thrombus weight
At the time of euthanasia, the IVC and the associated thrombus were 
removed and weighed for wet thrombus weight. The IVC was sepa-
rated from the aorta and surrounding tissue, and a segment from 
just below the left renal vein to the iliac bifurcation was removed 
for weighing. The lymph nodes were removed from the IVC prior to 
weighing. After determining thrombus weight, the vein wall was sepa-







F IGURE  2 The EIM was developed 
using a square wave stimulator 
and constant current unit (C, Grass 
Technologies), both of which are 
discontinued. Construction of a standard 
voltage- to- current converter (VIC)—circuit 
diagram shown in A and constructed circuit 
with standard DC power supply shown 
in B—provide a cost- effective alternative. 
The VIC was validated on the benchtop and 
then in vivo by thrombus weights at days 
2, 6, and 11 to the Grass S48 system (n = 5 
per group, mean ± SEM, D). DC, direct 
current; EIM, electrolytic inferior vena cava 
model; NS, not statistically significant; VIC, 
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2.5 | Thrombus volume assessment by MRI (in vivo)
The current and time dependency of the EIM was investigated in 
three groups of mice (standard, reduced current, or reduced time). 
Thrombus size was monitored in vivo by MRI at days 1, 2, 4, 6, 9, 11, 
and 14 following thrombus induction. Mice were anesthetized using 
2% isoflurane and imaged supine on a preclinical 7 Tesla MRI scanner. 
Respiration was monitored with a respiratory pillow (SA Instruments, 
Inc., NY, USA), and a PID controller was used to maintain the ani-
mal’s temperature at 37 ± 1°C via warm air circulation through the 
bore of the magnet. To assess thrombus volume, 2D time- of- flight 
gradient echo axial slices were acquired from the renal vessels to the 
iliac vessels (18 contiguous slices, each 1 mm thick; repetition time 
15 ms, echo time 4.9 ms, field of view 30 mm × 30 mm, flip angle 
20º, matrix 256 × 256 zero- filled to 512 × 512, in- plane resolution 
58.6 μm × 58.6 μm, number of excitations 3, imaging time 4 minutes). 
Thrombus volume was assessed by summing thrombus area in each 
axial slice (MRVision, Winchester, MA, USA).
2.6 | Quantitative real- time polymerase 
chain reaction
Ribonucleic acid (RNA) was isolated from the IVC wall by homog-
enizing in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) per the 
manufacturer’s protocol. Gene expression of PAI- 1, tissue plasmi-
nogen activator (t- PA), and urokinase plasminogen activator (u- PA) 
were determined by qRT- PCR using commercially available primers 
(mouse PAI- 1: PPM03093C, mouse t- PA PPM03855B, mouse u- PA 
PPM03095D) and SYBR master mix (SA Bioscience, Frederick, MD, 
USA) in a Rotor- Gene 3000 thermocycler (Corbett Life Science, San 
Francisco, CA, USA), as previously described.9,10 Gene expression was 
normalized to β- actin (mouse β- actin: PPM02945B) levels for each 
specimen.
2.7 | Immunohistochemistry
Harvested IVC samples containing thrombus were formalin fixed 
for 2 hours, dehydrated in alcohol, paraffin embedded, and cut into 
5 μm longitudinal sections. Nonspecific sites were blocked with nor-
mal serum, and sections were incubated with primary antibodies to 
Plasminogen (1:500, Genetex, Inc.; Catalog number GTX102877, 
Irvine, CA, USA) A species- specific ABC peroxidase kit (Vector 
Laboratories Inc., Burlingame, CA, USA) was used according to the 
manufacturer’s instructions for the corresponding secondary antibody 
and subsequent steps. Color development was performed with diam-
inobenzidine (DAB). Mosaic images were created via light microscopy 
(Nikon, Tokyo, Japan) under 40x magnification and quantification of 
percent positive staining was performed as previously described.11
2.8 | PAI- 1 activity assay
500 μL of blood was collected by cardiocentesis at harvest using a 
syringe with 0.05 mL of sodium citrate, and active and total PAI- 1 
was determined as previously described.12 In brief, to measure ac-
tive murine PAI- 1 concentrations in plasma samples, human u- PA 
(rheotromb) was coupled to carboxylated beads (Luminex, Austin, TX, 
USA) and used to capture active PAI- 1. A standard curve was gener-
ated using known concentrations of murine PAI- 1 in PAI- 1 depleted 
mouse plasma (Molecular Innovations, Novi, MI, USA). The assay 
was performed by adding 25 μL of either the standards or samples 
to a 96 well plate filter plate (Millipore, Billerica, MA, USA). Each 
well then received 25 μL PBS- 1% BSA and 5000 beads in 30 μL of 
PBS- 1% BSA. The wells were incubated overnight in the dark at 4°C. 
The solution from each well was removed by vacuum suctioning and 
each well was washed twice with 200 μL PBS- 0.05% Tween- 20. 
The beads were mixed with continuous shaking in the dark at room 
temperature for 2 hours with 50 μL of 2 μg/mL biotin- labeled rabbit 
anti- mouse PAI- 1 (Molecular Innovations, Novi, MI). The wells were 
vacuum washed and 25 μL of 4 μg/mL streptavidin- R- phycoerythrin 
(Molecular Probes, Eugene, OR, USA) was added to each well, and 
the mixture incubated in the dark with continuous agitation at room 
temperature for 30 minutes. Finally, the solution was removed from 
each well by vacuum suctioning, the beads were washed three times 
with 200 μL of PBS- 0.05% Tween- 20, and 150 μL of sheath fluid was 
added for 5- 10 minutes. The beads were then read with a Luminex 
100 (Luminex, Austin, TX, USA), median setting, 100 μL sample size, 
100 events/bead.
2.9 | Statistical analysis
All statistical analyses were completed using GraphPad Prism 7 
(GraphPad Software, San Diego, CA, USA). Comparison of thrombus 
weight between the VIC and Grass S48 was performed using an un-
paired t test with Welch’s correction. A two- way ANOVA analysis 
using the Tukey’s multiple comparison test was performed between 
VIC groups for the current and time dependency investigation as well 
as comparison of immunohistological plasminogen expression be-
tween time points. Relative expression of t- PA, u- PA, and PAI- 1 in 
the vein wall as well as active circulating PAI- 1 was compared to true 
controls for each time point using two- way ANOVA with Dunnett’s 
multiple comparison test. A P value of ≤.05 was considered significant. 
Data was reported as mean ± standard error of the mean (SEM).
3  | RESULTS
3.1 | Voltage- to- current circuit provides cost- 
effective system for performing EIM
We constructed a voltage- to- current converter (VIC) powered by a 
common DC power supply to offer an equipment alternative to per-
form the EIM. The development of the VIC provided an added benefit 
of a significant cost reduction (Table 1). In vivo validation of the VIC 
was performed by comparing thrombus size by wet weight at days 2, 6, 
and 11 post thrombus induction to thrombi produced using the Grass 
S48. Thrombus weights were not significantly different between the 
VIC and Grass S48 at any of the time points studied (Figure 2).
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3.2 | Thrombus size in EIM is both current and 
time dependent
The dependence of thrombus size on the supplied current and dura-
tion of application in the EIM was assessed by MRI from day 1 to 14 
post- thrombosis to enable tracking of thrombus size (via volume) in 
the same mouse over time. Time- of- flight imaging confirmed continu-
ous blood flow at peak thrombus size, day 2 post- thrombus initiation 
(Figure 3). Reduction of either current or time resulted in significantly 
smaller thrombus volume at all time points compared to standards (at 
day 2: 20.5 ± 1.3 mm3 standard vs 5.88 ± 0.7 mm3 reduced current 
vs 5.93 ± 0.6 mm3 reduced time, P < .05) (Figure 3). Interestingly, no 
statistical differences were found between the two modified groups. 
Importantly, thrombus size within each group was highly consistent 
between mice (coefficient of variation at day 2: controls 11%, reduced 
current 20%, reduced time 19%).
3.3 | The fibrinolytic system is suppressed in 
acute VT
The fibrinolytic system was investigated in the EIM at days 2, 6, and 
11. Qualitatively, positive immunostaining for plasminogen was ini-
tially found along the perimeter day 2, with distribution throughout 
the thrombus at days 6 and 11. Maximum staining was measured at 
day 6 (Figure 4). Active circulating PAI- 1 was significantly increased 
compared to true controls at days 2 and 11, with peak concentra-
tion at day 2 post thrombus induction (day 2: 2764 ± 120 pg/mL, 
day 11: 1775 ± 292 pg/mL vs. controls: 1063 ± 140 pg/mL, P < .05) 
(Figure 5). Interestingly, active circulating PAI- 1 at day 6 was not dif-
ferent from true controls, indicating a dynamic process of thrombus 
burden with changing thrombus composition. PAI- 1 expression in the 
IVC wall paralleled active circulating PAI- 1 expression (Figure 5). Vein 
wall PAI- 1 expression peaked at day 2, with a down- regulation trend 
of t- PA and u- PA at the same time point (P = NS). The opposite PAI- 1 
to t- PA and u- PA relationship was observed at day 11 (Figure 5).
4  | DISCUSSION
Animal models provide critical insight to understanding the mecha-
nisms of VT. However, there is no single model that can replicate the 
complexities of deep vein thrombosis. Moreover, model selection 
should be driven by the specific research question. Thus, a deep un-
derstanding of each available animal model including detailed charac-
terization is necessary for choosing the appropriate model for a given 
research question. The EIM is the only currently available mouse 
model that provides both thrombus size consistency and maintained 
blood flow in the IVC and around the thrombus independently of the 
time point investigated, which is favorable for systemically adminis-
tered therapeutic investigations.
The EIM was originally described using a stimulator and con-
stant current unit from Grass Technologies to follow the procedures 
used by Luchessi and collaborators13 in their canine coronary artery 
thrombosis model. This equipment was expensive and has since been 
discontinued. Alternative compatible stimulator and constant current 
units are difficult to find, but products from a Japanese company 
Nihon Kohden have been used.5 This equipment also can be expen-
sive, amounting to several thousands of dollars (Table 1). Thus, the 
high cost and discontinuation of the originally described equipment 
warranted an update to improve accessibility and characterization of 
the EIM.
Induction of thrombosis in EIM is accomplished by application of a 
very small constant current. In the original model description, this was 
regulated by the constant current unit (CCU1, Grass Technologies), 
which was powered by a compatible stimulator providing a very high 
voltage (150 V). The unit required this high voltage input to achieve 
accuracy in delivering 250 μA. Alternative current sources, however, 
do not require high voltage sources, eliminating the need for a high- 
voltage stimulator. Other constant current sources sold typically do 
not provide a range sufficiently low for this application. We chose to 
implement an operational amplifier constant current source for cost 
effectiveness, which we powered with a common DC power supply 
that many labs will have readily available. The VIC was validated on the 
bench using a multimeter and in vivo by comparing thrombus weight 
at days 2, 6, and 11, yielding results that were not statistically different 
from the stimulator and constant current unit. Thus, the model may be 
implemented at costs comparable to other murine models which only 
require a surgical scope and anesthesia machine.
Recently, a Japanese group presented a modification to the original 
EIM description to study a pro- thrombotic phenotype.5 Typically, max-
imum thrombus burden is observed at day 2 with a thrombus- to- lumen 
ratio of 3:1 making this method very suitable to study “thrombus re-
duction”, an attractive option when it comes to drug development and 
testing the potential role of pharmaceutical compounds for VT. Banno 
et al. adapted the original EIM by modifying the time (10 minutes in-
stead of 15 minutes) and the current (200 μA instead of 250 μA), re-
sulting in a smaller initial thrombus size for control mice, allowing them 
adequate sensitivity to detect larger thrombi in pro- coagulant mice. 
Their modification relied on the current and time dependency of the 
TABLE  1 Equipment required and price ranges for the previously 
described system compared to the VIC. Sample product numbers are 
provided for each component for reference
Previously Described System
Stimulator: $2000- $5000
Grass S48 Square Wave Stimulator1
Nihon Kohden SEN- 34015
Compatible Constant Current Unit $200- $2100
Grass CCU1 1
Nihon Kohden SS- 203J5
VIC
DC Power Supply $500
Agilent E3630A
VIC Circuit – 2 operational amplifiers, 1 resistor $10
AD620, AD705
VIC, voltage to current converter.
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model, but also opened the question of how individual modifications 
of these variables would influence the dynamics of thrombogenesis 
and resolution.
Taking advantage of MRI to follow each mouse over time, we per-
formed EIM with the original descriptive technique and in two exper-
imental groups—one with a reduced current of 100 μA and one with 
reduced time to 7.5 minutes. The results of this experiment demon-
strated thrombus size in this model is current and time dependent, 
and that these modifications still produce highly consistent thrombus 
size. These results corroborate the flexibility of the EIM to fine tune 
the model to a desired thrombus size for a specific research question. 
Of note, modifications served to decrease either current or time rather 
than increase. This is because in our experience with the development 
of this methodology, we concluded that 250 μA was the highest safe 
current without inducing off- target pathology (we observed lower 
limb paralysis with currents beyond 250 μA, independent of the time 
of application; observational data).
The recently completed ATTRACT trial investigated the impact of 
prompt thrombus removal via pharmacomechanical catheter directed 
thrombolysis (PCDT) on post thrombotic syndrome.14 PCDT involves 
both mechanical and chemical lysing of the thrombus from a catheter- 
based device embedded within the thrombus. Currently, there are 
no fibrinolytic drugs with FDA approval for the treatment of VT.15 
However, the use of t- PA as a chemical lysing agent is commonly used 
in endovascular procedures (“off- label” use). Its mechanism of action 
is conversion of plasminogen into plasmin, which breaks down fibrin. 
Thus, studying plasminogen content in this VT model provides a plat-
form for further investigations from both a biological and therapeutic 
perspective. The continuous blood flow channel in the EIM at all time 
points provides the possibility of direct drug access to the thrombus, 
even with systemically delivered therapies. However, before we move 
to therapeutics, the fibrinolytic system should be characterized in 
each animal model, as we did for this methodology (EIM). Our experi-
ments addressed plasminogen concentration at different time points, 
gene expression of markers of the fibrinolytic system (PAI- 1, u- PA and 
t- PA) in the vein wall directly in the area where the thrombus occurred, 
and active circulating PAI- 1.
Plasminogen, the inactive precursor of the enzyme plasmin 
which degrades fibrin, is activated by t- PA and u- PA. Interestingly, 
the immunohistochemistry for plasminogen showed higher total 
concentrations at day 6, with plasminogen arranged from the throm-
bus perimeter (day 2) towards the center of the thrombus over time. 
This centripetal integration suggests that blood flow access to the 
thrombus may play an important role in the fibrinolytic process. 
Understanding plasminogen dynamics may provide basic science in-
sights that could lead to a better understanding of therapeutic effi-
cacy at different stages of VT.
PAI- 1, one of the key inhibitors of t- PA and u- PA, was measured 
by gene expression in the vein wall and in its active circulating form. 
Total circulating PAI- 1 correlated with PAI- 1 gene expression in the 
vein wall, and interestingly, the peak of PAI- 1 was observed at day 
2, coinciding with the decreased expression of t- PA and u- PA. Taken 
together, this information supports that there is an impairment of the 
fibrinolytic system activity at day 2 (acute VT) favoring the develop-
ment of a thrombus. This is aligned with previous work demonstrating 
that PAI- 1 levels peaked at day 2 in the total IVC ligation model, which 
is considered a blood stasis model.12 The impairment of the fibrinolytic 
system during acute VT suggests that VT is not only attributable to 
coagulation processes, but also a decrease in the fibrinolytic system, 
regardless of blood flow conditions. This insight not only improves our 
knowledge of the model but also increases our understanding of VT 
and is aligned with previous human VT publications.16
F IGURE  3  (A) Contiguous axial MR 
images were used to quantify thrombus 
volume. Axial sections at the approximate 
midpoint of the thrombus at day 2 are 
shown for each group. Blood flow is visible 
surrounding the thrombus in all groups. 
The IVC is outlined in blue, the thrombus 
in green, and the aorta in red. Schematic 
representation of the thrombus is shown to 
the right of the MR images to highlight the 
thrombus size at day 2. (B) Modifications 
to the model demonstrate the current 
and time dependency of thrombus size 
(n = 3 per group, mean ± SEM) in the 
EIM, as measured by MRI. Time points 
were compared across groups, *P < .05. 
IVC, inferior vena cava; MRI, magnetic 
resonance imaging
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In conclusion, we have demonstrated that the EIM can be 
performed using a VIC with the added benefit of reduced cost. 
Thrombus size in the EIM is both current and time dependent. 
We characterized the dynamics of thrombus resolution in reduced 
current and time of application experiments, further confirming 
the flexibility of this model to study both anti- thrombotic and pro- 
thrombotic conditions. Regardless of the current and time of appli-
cation used, this model generates thrombi that are highly consistent 
in size, as was demonstrated previously with thrombus weight and 
ultrasound,2 and now by MRI. Additionally, the EIM can be used to 
investigate the fibrinolytic system under flow conditions. The func-
tionality of the fibrinolytic system increases over time as t- PA and 
u- PA are up- regulated and plasminogen disseminates throughout 
the thrombus, providing insights for improving future therapeu-
tic approaches. Hence, the EIM provides a cost- effective, flexi-
ble pre- clinical tool for studying the fibrinolytic system in venous 
thrombosis.
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